Modus Therapeutics Holding AB
29 Jun - 13 Jul 2021IPO
Karolinska Developments portfolio company Modus Therapeutics is a Swedish biotech company that develops sevuparin for diseases with highly unmet medical needs. The company’s focus in the short term is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition.
Patients suffering from sepsis are at risk of developing septic shock and multi-organ failure. Septic shock is one of the most common causes of death in intensive care units with a mortality rate that usually exceeds 30 percent. There is currently no specific pharmaceutical treatment available for the treatment of sepsis. This makes the condition one of the most costly to treat in hospital care. In 2019, US healthcare costs for patients with sepsis were estimated at $ 23 billion.
Modus Therapeutics drug candidate sevuparin has been documented in a number of preclinical and clinical trials and is covered by patent protection until at least 2032. New preclinical research, conducted in collaboration with a research group at Karolinska Institutet, has shown that sevuparin significantly alleviates the effects of severe systemic inflammation, which occurs in connection with sepsis, among other things.
Read more on the company's website
The offer in summary
Subscription period: 29 June - 13 July 2021
Subscription price: SEK 6.40 per unit, which corresponds to SEK 6.40 per share. One (1) unit consists of one (1) share and one (1) warrant of series TO 1. The warrants are free of charge. Brokerage is not canceled.
Minimum acquisition : 1000 units, which corresponds to SEK 6,400.00
Volume of issuance: The offer comprises a maximum of 5,156,300 units, which corresponds to 5,156,300 shares and 5,156,300 warrants. The total Offer Amount amounts to a maximum of approximately MSEK 33.
To register an interest in acquiring units in Modus Therapeutics IPO, you should contact your bank. Please note that not all banks have the opportunity to assist their customers with a report and in the event that your bank cannot help you, please contact Nordic Issuing (info@nordic-issuing.se) for information on how to proceed.
The following banks offer a guaranteed opportunity to subscribe for units in Modus Therapeutics:
Nordnet (Sweden): www.nordnet.se
Nordnet (Denmark): www.nordnet.dk
Nordnet (Norway): www.nordnet.no
Nordnet (Finland): www.nordnet.fi
Avanza: www.avanza.se
A warrant of series TO 1 entitles the holder to subscribe for one (1) new share in the company at a subscription price of a minimum of SEK 7.30 to a maximum of SEK 8.80 per share in cash. The subscription price amounts (within the interval above) to 70 percent of the average volume-weighted price for the share according to First North’s official price statistics during the period of 20 trading days ending two banking days before the exercise period begins. The subscription price will be announced the day before the first day of the useful life. Amounts in excess of the quota value shall be added to the free share premium fund.
Subscription of shares in the company with the support of warrants of series TO 1 can take place during the period from 19 May to 9 June 2022.
